Collaboration Momentum ITI has active collaborations around antibodies and vaccines, signaling openness to co development and licensing with pharma partners across oncology, infectious disease, and immune therapies leveraging the UNITE platform.

DC Vaccine Asset ITI-1000 is a cancer cell vaccine based on autologous dendritic cells loaded with CMV pp65 mRNA, offering potential for oncology development and partnerships in trials and autologous vaccine manufacturing.

Platform Versatility UNITE enables intracellular targeting to elicit broad immune responses across cancer, allergy, and infectious diseases, supporting cross indication partnerships and platform licensing discussions with large companies.

Small Company Advantage With a lean team and mid range revenue, ITI can offer flexible milestone driven licensing and collaboration terms, enabling faster deal closure and iterative joint development programs.

Market Differentiation Position ITI as a differentiated platform company focused on universal intracellular targeting and broad immune responses to attract partners in CMV related cancer vaccines and immunotherapies.